Reproductive and contraceptive issues in chronically ill adolescents

references

• Bearinger LH, Sieving RE, Ferguson J, et al. Global perspectives on the sexual and reproductive health of adolescents: Patterns, prevention, and potential. Lancet 2007;369:1220–31.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Medical eligibility criteria for contraceptive use, 4th edn. Geneva: WHO2009.
   Google Scholar
• Newacheck PW, McManus MA, Fox HB. Prevalence and impact of chronic illness among adolescents. AJDC 1991;145:1367–73.
   PubMedGoogle Scholar
• Centers for disease control and prevention surveillance summaries. MMWR 2008;57(SS12):1–27.
   PubMedGoogle Scholar
• Shah P, Norlin C, Logsdon L, et al. Gynecological care for adolescents with disability: Physician comfort, perceived barriers, and potential solutions. J Pediatr Adolesc Gynecol 2005;18:101–4.
   PubMedGoogle Scholar
• Greydanus DE, Hatim HA. Sexuality issues and gynecologic care of adolescents with developmental disabilities. Pediatr Clin North Am 2008;55:1315–35.
   PubMed Web of Science ®Google Scholar
• Greydanus DE, Matytstina LA. Contraception in adolescent females with chronic illness: A clinical review. Int J Child Adolesc Health 2010;3:222–31.
   Google Scholar
• Greydanus DE, Omar HA, Tsitsika AK. Obesity and contraception. Obesity and adolescence: A public health concern. In Omar HA, Greydanus DE, Patel DR, et al, eds. New York: Nova Science Publishers 2009: 73–84.
   Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010;81: 474–80.
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: A randomized controlled trial. Obstet Gynecol 2010;116:275–83.
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data. Fertil Steril 2002;77:s13–s18.
   PubMed Web of Science ®Google Scholar
• Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002;7:19–26.
   PubMed Web of Science ®Google Scholar
• Apter D, Borsos A, Baumgärtner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37–51.
   PubMed Web of Science ®Google Scholar
• Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304–11.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843:1–290.
   PubMed Web of Science ®Google Scholar
• Schonau E. The peak bone mass concept: Is it still relevant? Pediatr Nephrol 2004;19:825–31.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: A systematic review. Contraception 2006;73:470–87.
   PubMed Web of Science ®Google Scholar
• Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: Results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64–72.
   PubMedGoogle Scholar
• Chiou CF, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003;68:3–10.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. Committee on Adolescent Health Care. Intrauterine device and adolescents. Obstet Gynecol 2007;110:1493–5.
   PubMedGoogle Scholar
• McNaught J. Adolescents and IUCDs – Not a contraindication. J Pediatr Adolesc Gynecol 2006;19:303–5.
   PubMedGoogle Scholar
• Lacy J. Clinic opinions regarding IUCD use in adolescents. J Pediatr Adolesc Gynecol 2006;19:301–3.
   PubMedGoogle Scholar
• Kjaer K, Hagen C, Sando SH, et al. Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulin-dependent diabetes mellitus compared to controls. J Clin Endocrinol Metab 1992;75:524–9.
   PubMed Web of Science ®Google Scholar
• Widom B, Diamond MP, Simonson DC. Alterations in glucose metabolism during menstrual cycle in women with IDDM. Diabetes Care 1992;15:213–20.
   PubMed Web of Science ®Google Scholar
• Petersen KR, Skouby SO, Vedel P, et al. Hormonal contraception in women with IDDM: Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care 1995;18:800–6.
   PubMed Web of Science ®Google Scholar
• Jones KP, Wild RA. Contraception for patients with psychiatric or medical disorders. Am J Obstet Gynecol 1994;170:1575–80.
   PubMed Web of Science ®Google Scholar
• Verhaege J. Hormonal contraception in women with the metabolic syndrome: A narrative review. Eur J Contracept Reprod Health Care 2010;15:305–13.
   PubMed Web of Science ®Google Scholar
• Owens K, Honebrink A. Gynecologic care of medically complicated adolescents. Pediatr Clin North Am 1999;46:631–42.
   PubMed Web of Science ®Google Scholar
• Teal SB, Ginosar DM. Contraception for women with chronic medical conditions. Obstet Gynecol Clin North Am 2007;34:113–26.
   PubMed Web of Science ®Google Scholar
• Weber G, Vigone MC, Stroppa L, et al. Thyroid function and puberty. J Pediatr Endocrinol Metab 2003;16:253–7.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Mestman J. Hormonal contraception in women with common medical conditions: Benefits and risk of use. Dialogues Contracept 2004;8:1–7.
   Google Scholar
• Sänger N, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use. Contraception 2008;77:420–5.
   PubMed Web of Science ®Google Scholar
• Brenner SH, Lessing JB, Quagliarello J, et al. Hyperprolactinemia and associated pituitary prolactinomas. Obstet Gynecol 1985;65:661–4.
   PubMed Web of Science ®Google Scholar
• Kars M, Dekkers OM, Pereira AM, et al. Update in prolactinomas. Neth J Med 2010;68:104–12.
   PubMed Web of Science ®Google Scholar
• Gittes EB, Strickland JL. Contraceptive choices for chronically ill adolescents. Adolesc Med 2005;16:635–44.
   Google Scholar
• Ott J, Promberger R, Kaufmann U, et al. Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation. Arch Gynecol Obstet 2009;280:811–4.
   PubMed Web of Science ®Google Scholar
• de Teresa E, Vera A, Ortigosa J, et al. Interaction between anticoagulants and contraceptives: An unsuspected finding. Br Med J 1979;2:1260–1.
   PubMed Web of Science ®Google Scholar
• Comp PC, Zacur HA. Contraceptive choices in women with coagulation disorders. Am J Obstet Gynecol 1993;168:1990–3.
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Morgante G, et al. Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives. Contraception 2001;64:145–8.
   PubMed Web of Science ®Google Scholar
• Emans SJ. Contraception. Pediatric and adolescent gynecology, In Emans SJ, Laufer MR, Goldstein DP, eds. 5th edn. Philadelphia: Lippincott Williams & Wilkins 2005: 760–843.
   Google Scholar
• Heroux K. Contraceptive choices in medically ill adolescents. Semin Reprod Med 2003;21:389–98.
   PubMed Web of Science ®Google Scholar
• Davidoff F, Tishler S, Rosoff C. Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med 1973;289:552–5.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339: b2890.
   PubMed Web of Science ®Google Scholar
• Heinemann LA, Assmann A, DoMinh T, et al. Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:67–73.
   PubMedGoogle Scholar
• Vasilakis C, Jick H, del Mar Meleto-Montes M. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999;354:1610–11.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998;57:315–24.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999;72:646–51.
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists Guideline No. 40. Venous thromboembolism and hormonal contraception. October 2004.
   Google Scholar
• The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990;43:703–9.
   PubMed Web of Science ®Google Scholar
• Haemostasis and Thrombosis Task Force. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512–28.
   PubMed Web of Science ®Google Scholar
• James AH. More than menorrhagia: A review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005;11:295–307.
   PubMed Web of Science ®Google Scholar
• Shankar M, Lee CA, Sabin CA, et al. von Willebrand disease in women with menorrhagia: A systematic review. BJOG 2004;111:734–40.
   PubMed Web of Science ®Google Scholar
• Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97: 630–6.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. Von Willebrand disease in women. ACOG Committee Opinion Number 451. Obstet Gynecol 2009;114:1439–43.
   PubMedGoogle Scholar
• Greydanus DE, Omar HA, Tsitsika AK, et al. Menstrual disorders in adolescent females: Current concepts. Dis Mon 2009;55:45–113.
   PubMed Web of Science ®Google Scholar
• James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: Consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009;201:12.el–12.e8.
   Google Scholar
• Robinson GE, Burren T, Mackie IJ, et al. Changes in haemostasis after stopping the combined contraceptive pill: Implications for major surgery. BMJ 1991;302: 269–71.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin 18: The use of hormonal contraception in women with coexisting medical conditions. Compendium of Selected Publications. Washington, DC: 2004: 674–87.
   Google Scholar
• Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350: 886–95.
   PubMed Web of Science ®Google Scholar
• Byrne J, Fears T, Gail M, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788–93.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Schilsky R. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 1989;16:425–36.
   PubMed Web of Science ®Google Scholar
• Laufer MR, Rein MS. Treatment of abnormal uterine bleeding with gonadotropin-releasing hormone analogues. Clin Obstet Gynecol 1993;36:668–78.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261–6.
   PubMed Web of Science ®Google Scholar
• Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke 1998;29:2277–84.
   PubMed Web of Science ®Google Scholar
• Hatcher RA, Zieman M, Cwiak C, et al. Managing contraception 2004–2005. Tiger, Georgia: Bridging the Gap Foundation 2004.
   Google Scholar
• Morrell M. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003;44:11–20.
   PubMed Web of Science ®Google Scholar
• Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43: 341–6.
   PubMed Web of Science ®Google Scholar
• Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612–9.
   PubMed Web of Science ®Google Scholar
• Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995;36:676–81.
   PubMed Web of Science ®Google Scholar
• Neinstein L. Contraception in women with special medical needs. Compr Ther 1998;24:229–50.
   PubMedGoogle Scholar
• Burkett AM, Hewitt GD. Progestin only contraceptives and their use in adolescents: Clinical options and medical indications. Adolesc Med 2005;16:553–67.
   Google Scholar
• Mattson RH, Rebar RW. Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 1993;168:2027–32.
   PubMed Web of Science ®Google Scholar
• Mattson RE, Cramer JA, Darney PD, et al. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:2961–2.
   PubMed Web of Science ®Google Scholar
• Vessey M, Painter R, Yeates D. Oral contraception and epilepsy: Finding in a large cohort study. Contraception 2002;66:77–9.
   PubMed Web of Science ®Google Scholar
• Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783–7.
   PubMed Web of Science ®Google Scholar
• Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151–4.
   PubMed Web of Science ®Google Scholar
• Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892–6.
   PubMed Web of Science ®Google Scholar
• Back DJ, Orme ML. Drug interactions. Pharmacology of the contraceptive steroidsIn Goldzieher JW, Fotherby K, eds. Philadelphia: Lippincott-Raven 1994: 407.
   Google Scholar
• Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263–72.
   PubMed Web of Science ®Google Scholar
• Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000;38:355–65.
   PubMed Web of Science ®Google Scholar
• Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48:484–9.
   PubMed Web of Science ®Google Scholar
• Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33: 23–9.
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43: 697–702.
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions. Int J Gynaecol Obstet 2001;75:93–106.
   PubMed Web of Science ®Google Scholar
• Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: A review of the past 10 years, part I. J Am Acad Child Adolesc Psychiatry 1996;35:1427–39.
   PubMed Web of Science ®Google Scholar
• Saluja G, Iachan R, Scheidt PC, et al. Prevalence of and risk factors for depressive symptoms among young adolescents. Arch Pediatr Adolesc Med 2004;158:760–5.
   PubMed Web of Science ®Google Scholar
• Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002;70:229–40.
   PubMed Web of Science ®Google Scholar
• Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 2007;120:e1313–26.
   PubMed Web of Science ®Google Scholar
• Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol 2002;187:551–5.
   PubMed Web of Science ®Google Scholar
• Greydanus DE, Calles JL, Patel DR. Child and adolescent depression. Pediatric and adolescent psychopharmacology. In Greydanus DE, Calles JL, Patel DR, eds. Cambridge, UK: Cambridge University Press 2008: 103–16.
   Google Scholar
• Magalhães PV, Kapczinski F, Kauer-Sant'Anna M. Use of contraceptive methods among women treated for bipolar disorder. Arch Womens Ment Health 2009;12:183–5.
   PubMed Web of Science ®Google Scholar
• Findling RL. Safety and tolerability of bipolar disorder treatment in youth. J Clin Psychiatry 2009;70: e44.
   PubMedGoogle Scholar
• Elliott GR, Smiga SM. Mood disorders in children and adolescents. Behavioral Pediatrics, In Greydanus DE, Patel DR, Pratt HD, eds. 2nd edn. Lincoln: iUniverse Inc. 2006: 589–617.
   Google Scholar
• Prasher VP. Down syndrome and thyroid disorders: A review. Downs Syndr Res Pract 1999;6:25–42.
   PubMedGoogle Scholar
• Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: Final thoughts. Epilepsia 2001;42: 311–5.
   PubMed Web of Science ®Google Scholar
• Cento RM, Ciampelli M, Proto C, et al. Neuroendocrine features of pubertal development in females with mental retardation. Gynecol Endocrinol 2001;15: 178–83.
   PubMed Web of Science ®Google Scholar
• ACOG Committee opinion. Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 2009; 114:1428–31.
   PubMedGoogle Scholar
• Hankoff LD, Darney PD. Contraceptive choices for behaviorally disordered women. Am J Obstet Gynecol 1993;168:1986–9.
   PubMed Web of Science ®Google Scholar
• Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon® on menstrual bleeding pat$132#terns. Eur J Contracept Reprod Health Care 2008;13:13–28.
   PubMed Web of Science ®Google Scholar
• Speroff L, Fritz MA. Long-acting methods of contraception. Clinical gynecologic endocrinology and infertility. In Speroff L, Fritz MA, eds. Philadelphia, PA: Lippincott Williams & Wilkins 2005: 949–69.
   Google Scholar
• American College of Obstetricians and Gynecologists. Depot medroxyprogesterone acetate and bone effects. ACOG Committee Opinion No. 415. Obstet Gynecol 2008;112:727–30.
   PubMedGoogle Scholar
• Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006;160:40–5.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Noncontraceptive uses of the levonorgestrel intrauterine system. ACOG Committee Opinion No.337. Obstet Gynecol 2006;107:1479–82.
   PubMedGoogle Scholar
• Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984;25:52–6.
   PubMed Web of Science ®Google Scholar
• Mayberry IF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: A case control study by European collaborative group. Gut 1986;27:821–5.
   PubMed Web of Science ®Google Scholar
• Khoo SK, Correy JF. Contraception and the high risk woman. Med J Aust 1981;1:60–8.
   PubMed Web of Science ®Google Scholar
• McCann MF, Potter LS. Progestin-only oral contraception: A comprehensive review. Contraception 1994; 50(6 Suppl. 1):S1–195.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Colditz GA, Hunter DJ, et al. A prospective study of symptomatic gallstones in women: Relation with oral contraceptives and other risk factors. Obstet Gynecol 1994;84:207–14.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum 2001;30:426–35.
   PubMed Web of Science ®Google Scholar
• Drossaers-Bakker KW, Zwinderman AH, van Zeben D, et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis 2002;61:405–8.
   PubMed Web of Science ®Google Scholar
• Balzano G, Fuschillo S, Melillo G, et al. Asthma and sex hormones. Allergy 2001;56:13–20.
   PubMed Web of Science ®Google Scholar
• Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350–62.
   PubMed Web of Science ®Google Scholar
• Tan KS. Premenstrual asthma: Epidemiology, pathogenesis and treatment. Drugs 2001;61:2079–86.
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Shah A. Menstrual-linked asthma. J Asthma 1997;34:539–45.
   PubMed Web of Science ®Google Scholar
• Shames RS, Heilbron DC, Janson SL, et al. Clinical differences among women with and without self-reported perimenstrual asthma. Ann Allergy Asthma Immunol 1998;81:65–72.
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Annual data report 2001. Bethesda, MD 2001.
   Google Scholar
• Frederiksen B, Lanng S, Koch C, et al. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment. Pediatr Pulmonol 1996;21:153–8.
   PubMed Web of Science ®Google Scholar
• Sawyer SM, Phelan PD, Bowes G. Reproductive health in young women with cystic fibrosis: Knowledge, behavior and attitudes. J Adolesc Health 1995;17:46–50.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick S, Stokes D, Rosenstein B, et al. Use of oral contraceptives in women with cystic fibrosis. Chest 1984;86:863–7.
   PubMed Web of Science ®Google Scholar
• Holley JL, Schmidt RJ, Bender FH, et al. Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 1997;29:685–90.
   PubMed Web of Science ®Google Scholar
• Laufer MR, Emans SJ. Gynecologic issues in young women with chronic diseases. Pediatric and adolescent gynecology, In Emans SJ, Laufer MR, Goldstein DP, eds. 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins2005: 893–938.
   Google Scholar
• Sawyer SM, Drew S, Yeo MS, et al. Adolescents with a chronic condition: Challenges living, challenges treating. Lancet 2007;369:1481–9.
   PubMed Web of Science ®Google Scholar